The current study indicated that there was no significant difference in the incidence of adverse effects, including abnormal INR, among patients with impaired renal function who received CFP–SUL 2 g/2 g Q12H and those who received 1 g/1 g Q12H for treatment of septicemia caused by Gram-negative organisms. Here, CFP is linked to Sepsis.